EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas..     ///    "EGFR gene copy number gains and KRAS/BRAF mutations have been reported to act as positive and negative predictors, respectively, of therapeutic response to EGFR targeted therapies in colorectal adenocarcinoma, a tumour type claimed to be genetically similar to ITAC. "